Want to see CH:SANN full AI Analyst Report?
SANN Stock Chart & Stats
CHF15.56
CHF0.36(2.42%)
At close: 4:00 PM EDT
CHF15.56
CHF0.36(2.42%)
Day’s Range― - ―
52-Week RangeCHF9.38 - CHF18.84
Previous CloseN/A
Volume65.72K
Average Volume (3M)73.14K
Market Cap
CHF218.76M
Enterprise ValueCHF271.86M
Total Cash (Recent Filing)CHF41.77M
Total Debt (Recent Filing)CHF41.27M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Apr 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.28
Shares Outstanding15,941,051
10 Day Avg. Volume87,110
30 Day Avg. Volume73,137
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)-13.88
Price to Sales (P/S)2.12
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.08
Revenue Forecast (FY)CHF91.57M
Bulls Say, Bears Say
Bulls Say
Strong Commercial GrowthRapid revenue and product-sales growth indicates accelerating adoption of AGAMREE and expanding commercial reach. If sustained, this momentum can improve operating leverage, support reinvestment in rare-disease opportunities, and strengthen Santhera’s position with prescribers and partners over the coming quarters.
Expanding Market AccessBroadening launches and reimbursement progress create a larger addressable commercial base for the company’s lead product. Expansion across major European markets, supported by distributor coverage, can diversify revenue sources and provide a durable foundation for continued product adoption beyond the initial launch markets.
Strategic Licensing PlatformThe Nxera partnership extends Santhera’s geographic reach without requiring the company to commercialize every market directly. Upfront cash, potential milestones and royalties can provide non-linear revenue opportunities while validating AGAMREE’s international potential and preserving participation in future regional growth.
Bears Say
Negative Equity And Higher DebtNegative equity combined with materially higher debt weakens financial resilience and reduces flexibility to absorb execution setbacks. The capital structure may constrain investment choices and increase dependence on successful commercialization, particularly while the company continues transitioning toward sustainable profitability.
Persistent Cash BurnRecurring operating and free-cash-flow deficits show that the business has not yet consistently funded itself from operations. Continued cash burn can limit Santhera’s ability to invest in additional assets or absorb delays, making progress toward durable cash generation an important condition for financial stability.
Pricing And Reimbursement PressureLower German pricing could reduce revenue and margins in an important market, while delayed French reimbursement postpones access to another major opportunity. Together, these issues may temper near-term commercial conversion and make the company’s growth targets more dependent on other markets and partners.
Santhera Pharmaceuticals Holding News
SANN FAQ
What was Santhera Pharmaceuticals Holding’s price range in the past 12 months?
Santhera Pharmaceuticals Holding lowest stock price was CHF9.38 and its highest was CHF18.84 in the past 12 months.
What is Santhera Pharmaceuticals Holding’s market cap?
Santhera Pharmaceuticals Holding’s market cap is CHF218.76M.
When is Santhera Pharmaceuticals Holding’s upcoming earnings report date?
Santhera Pharmaceuticals Holding’s upcoming earnings report date is Apr 29, 2027 which is in 199 days.
How were Santhera Pharmaceuticals Holding’s earnings last quarter?
Santhera Pharmaceuticals Holding released its earnings results on Sep 30, 2026. The company reported -CHF1.5 earnings per share for the quarter, missing the consensus estimate of CHF0.17 by -CHF1.67.
Is Santhera Pharmaceuticals Holding overvalued?
According to Wall Street analysts Santhera Pharmaceuticals Holding’s price is currently Overvalued.
Does Santhera Pharmaceuticals Holding pay dividends?
Santhera Pharmaceuticals Holding does not currently pay dividends.
What is Santhera Pharmaceuticals Holding’s EPS estimate?
Santhera Pharmaceuticals Holding’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Santhera Pharmaceuticals Holding have?
Santhera Pharmaceuticals Holding has 15,941,051 shares outstanding.
What happened to Santhera Pharmaceuticals Holding’s price movement after its last earnings report?
Santhera Pharmaceuticals Holding reported an EPS of -CHF1.5 in its last earnings report, missing expectations of CHF0.17. Following the earnings report the stock price went up 2.785%.
Which hedge fund is a major shareholder of Santhera Pharmaceuticals Holding?
Currently, no hedge funds are holding shares in CH:SANN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Santhera Pharmaceuticals Holding
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
SANN Company Deck
SANN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive, with substantial revenue growth, improving operating performance, expanding market access, strong commercial uptake and supportive long-term efficacy and safety data. The main challenges were the unexpected 8.5% German pricing discount, an anticipated cash decline in the first half of 2027, the delayed French launch, ongoing reimbursement work in several markets and uncertainty around future partnering and additional-asset financing. Overall, the breadth and strength of the reported commercial and clinical progress significantly outweighed the disclosed challenges.View all CH:SANN earnings summariesTechnical Analysis
Addex Therapeutics
―
Molecular Partners AG
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
MindMaze Therapeutics Holding SA
―